# Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD

> **NCT06243614** · PHASE3 · RECRUITING · sponsor: **Beijing Union Pharmaceutical Factory Ltd** · enrollment: 410 (estimated)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Buagafuran capsules, 15mg/ capsule
- **DRUG:** Buspirone tablets, 5mg/ tablet
- **DRUG:** Buagafuran capsules mimic, 0mg/ capsule
- **DRUG:** Buspirone tablets mimic, 0mg/ tablet

## Key facts

- **NCT ID:** NCT06243614
- **Lead sponsor:** Beijing Union Pharmaceutical Factory Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06243614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06243614, "Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06243614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*